REGENXBIO (NASDAQ:RGNX) Trading Down 6.1% – Here’s Why

REGENXBIO Inc. (NASDAQ:RGNX) was down 6.1% during trading on Friday . The company traded as low as $10.62 and last traded at $10.5940. 194,626 shares were traded during trading, a decline of 87% from the average session volume of 1,452,026 shares. The stock had previously closed at $11.28.

Key Headlines Impacting REGENXBIO

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Strong Q2 results: REGENXBIO reported earnings of $0.43 per share, well above analyst estimates of $0.08–$0.12, while revenue of $108.0 million exceeded the $97.6 million consensus estimate. The result compares with a $1.38-per-share loss in the year-ago quarter. REGENXBIO Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Key pipeline milestones remain on track: The company said its RGX-202 gene therapy filing for Duchenne muscular dystrophy is expected to begin in the third quarter of 2026, with potential accelerated approval in the second half of 2027. RGX-121 for Hunter syndrome is also targeted for resubmission in Q3 2026, while pivotal wet age-related macular degeneration data are expected in Q4 2026. REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: Improved financial flexibility: More than $200 million of new capital raised in July increased pro forma cash, cash equivalents and marketable securities to over $310 million and extended the cash runway into the fourth quarter of 2027. This reduces near-term financing pressure as the company advances its programs. REGENXBIO Outlines Cash Runway
• Neutral Sentiment: Barclays maintained an Equal Weight rating and set a $12 price target, implying potential upside from recent trading levels but signaling a balanced view rather than a strong bullish recommendation. Barclays Rating Update
• Negative Sentiment: Profitability remains weak: Despite the quarterly beat, REGENXBIO continues to report a deeply negative net margin and return on equity, and analysts expect a full-year loss. Investors may therefore view the earnings improvement as less durable if it depends on licensing or other non-recurring revenue.
• Negative Sentiment: Material execution risk remains: The stock’s valuation and future upside depend heavily on successful regulatory filings, clinical data and eventual commercialization of its gene-therapy programs. Delays, safety concerns or disappointing trial results could pressure RGNX.

Analysts Set New Price Targets

Several equities analysts recently issued reports on RGNX shares. HC Wainwright reiterated a “buy” rating and issued a $26.00 target price on shares of REGENXBIO in a research note on Wednesday, July 1st. Robert W. Baird raised their price target on shares of REGENXBIO from $27.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, June 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of REGENXBIO in a report on Monday, June 8th. Leerink Partners upped their price objective on shares of REGENXBIO from $17.00 to $18.00 and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Finally, Barclays lowered shares of REGENXBIO from an “overweight” rating to a “hold” rating in a research note on Friday. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, REGENXBIO has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

REGENXBIO Trading Down 5.0%

The stock has a market cap of $554.22 million, a PE ratio of -2.83 and a beta of 0.94. The business has a 50-day moving average price of $10.02 and a 200-day moving average price of $9.43.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.08 by $0.35. The company had revenue of $108.02 million during the quarter, compared to analyst estimates of $97.63 million. REGENXBIO had a negative net margin of 112.58% and a negative return on equity of 220.07%. Equities analysts expect that REGENXBIO Inc. will post -3.96 earnings per share for the current year.

Insider Buying and Selling at REGENXBIO

In related news, insider Steve Pakola sold 36,725 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $12.86, for a total transaction of $472,283.50. Following the completion of the transaction, the insider owned 213,009 shares in the company, valued at $2,739,295.74. This represents a 14.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have sold 73,803 shares of company stock worth $886,937. 14.22% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On REGENXBIO

Several large investors have recently bought and sold shares of the company. Versant Capital Management Inc lifted its position in shares of REGENXBIO by 60.4% in the second quarter. Versant Capital Management Inc now owns 2,741 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 1,032 shares in the last quarter. Aquatic Capital Management LLC purchased a new stake in shares of REGENXBIO during the third quarter worth approximately $37,000. Entropy Technologies LP purchased a new stake in shares of REGENXBIO during the first quarter worth approximately $87,000. Captrust Financial Advisors acquired a new position in REGENXBIO in the 2nd quarter valued at $85,000. Finally, Balyasny Asset Management L.P. acquired a new position in REGENXBIO in the 4th quarter valued at $150,000. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.